Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy | Zendy

Laura K. Ferris | Zendy; Burkhard Jansen | Zendy; Jonhan Ho | Zendy; Klaus J. Busam | Zendy; Kenneth G. Gross | Zendy; Doyle Hansen | Zendy; John P. Alsobrook | Zendy; Zuxu Yao | Zendy; Gary L. Peck | Zendy; Pedram Gerami | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy

Author(s) -

Laura K. Ferris,

Burkhard Jansen,

Jonhan Ho,

Klaus J. Busam,

Kenneth G. Gross,

Doyle Hansen,

John P. Alsobrook,

Zuxu Yao,

Gary L. Peck,

Pedram Gerami

Publication year - 2017

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2017.0473

Subject(s) - medicine , biopsy , melanoma , lesion , pathology , dermatology , cancer research

Expression of long intergenic non-protein coding RNA 518 (LINC00518) and preferentially expressed antigen in melanoma (PRAME) genes, obtained via noninvasive adhesive patch biopsy, is a sensitive and specific method for detection of cutaneous melanoma. However, the utility of this test in biopsy decisions made by dermatologists has not been evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research